Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

NCT03661307 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

73

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Myelodysplastic Syndrome
Recurrent Acute Myeloid Leukemia
Recurrent Myelodysplastic Syndrome
Refractory Acute Myeloid Leukemia

Interventions

DRUG: Decitabine
DRUG: Quizartinib
DRUG: Venetoclax

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]